• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the Canadian Academy of Child and Adolescent Psychiatry >Adjunctive Trazodone and Depression Outcome in Adolescents Treated with Serotonin Re-uptake Inhibitors
【24h】

Adjunctive Trazodone and Depression Outcome in Adolescents Treated with Serotonin Re-uptake Inhibitors

机译：用5-羟色胺再摄取抑制剂治疗青少年的佐佐酮和抑郁结局

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives Recent published evidence suggests that adjunctive trazodone treatment may limit serotonin reuptake inhibitor (SRI) response in depressed adolescents in the context of a controlled trial. This study examined the effects of adjunctive trazodone on depression outcome in adolescents in a naturalistic treatment environment. Methods We conducted a cohort study through chart review of a clinical sample. Patients in our sample were 15 to 18 years of age treated with either a selective serotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor. The treatment took place in the setting of a partial hospitalization program at a tertiary care centre from 2009–2014. The main outcome measure was the change in Beck Depression Inventory II (BDI-II) score from admission to discharge. We compared this outcome in patients who were exposed to adjunctive trazodone treatment compared to adolescents who did not receive trazodone in the final four weeks of the program. Results Exposure to trazodone was significantly associated with non-response to treatment in our sample (n= 35; β1= ?7.76; 95% CI ?0.52 to – 15.0; p2 = 0.13). In exploring potential confounders, higher baseline BDI-II scores appeared to predict greater change in BDI-II scores from pre- to post-treatment. Conclusion In keeping with previous research, we found that trazodone exposure was associated with treatment non-response in adolescents taking SRIs. The findings should be interpreted cautiously since they are limited by small sample size. Future randomized controlled trials of trazodone in samples of adolescents taking SRIs for depression are warranted.
机译：目的最近发表的证据表明，在对照试验的背景下，辅助性曲唑酮治疗可能会限制抑郁症青少年的血清素再摄取抑制剂（SRI）反应。这项研究在自然治疗环境中研究了辅助曲唑酮对青少年抑郁结局的影响。方法我们通过对临床样本进行图表审查进行了队列研究。我们样本中的患者年龄在15至18岁之间，接受选择性5-羟色胺再摄取抑制剂或5-羟色胺和去甲肾上腺素再摄取抑制剂治疗。该治疗是在2009年至2014年期间在三级护理中心制定的部分住院计划中进行的。主要结局指标是从入院到出院的贝克抑郁量表II（BDI-II）得分的变化。我们比较了在方案最后四周未接受曲唑酮辅助治疗的患者与未接受曲唑酮治疗的青少年的这一结果。结果在我们的样本中，曲唑酮的暴露与治疗无反应显着相关（n = 35;β 1 =？7.76; 95％CI？0.52至– 15.0; p2 = 0.13 ）。在探索潜在的混杂因素时，较高的基线BDI-II评分似乎可以预测治疗前至治疗后BDI-II评分的较大变化。结论与先前的研究一致，我们发现曲唑酮暴露与服用SRI的青少年治疗无反应有关。由于发现的样本量小，因此应谨慎解释。将来有必要在接受SRI治疗抑郁症的青少年样本中进行曲唑酮的随机对照试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号